NCT03391804View on ClinicalTrials.gov

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

December 13, 2019

Study Completion Date

December 13, 2019

Conditions
Enteric HyperoxaluriaPrimary HyperoxaluriaHyperoxalemia
Interventions
DRUG

ALLN-177

ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks

Trial Locations (9)

10117

Charite Campus Berlin-Mitte, Medizinische Klinik mit Schwepunkt Nephrologie und Internistische Intensivmedizin, Berlin

55905

Mayo Clinic, Rochester

72212

Applied Research Center of Arkansas, Little Rock

85259

Mayo Clinic, Scottsdale

06519

Yale University School of Medicine, New Haven

SO16 6YD

Wellcome Trust Clinical Research Facility, Southampton

PR2 9HT

Royal Preston Hospital, Preston

LS1 3EX

Leeds General Infirmary, Leeds

NE7 7 DN

Freeman Hospital, Newcastle

Sponsors
All Listed Sponsors
lead

Allena Pharmaceuticals

INDUSTRY

NCT03391804 - Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia | Biotech Hunter | Biotech Hunter